IL13 and type 1 diabetes mellitus: In humans, IL4 transcript levels have been shown to be greatly reduced in new-onset T1DM (22), and it has been speculated that IL13, as an anti-inflammatory cytokine and a mediator of the Th2 pathway represents a potential therapeutic approach in prevention of the T1DM (23–26).